Blog

October 2013, Santa Clara, California
Oral Presentation: High resolution MS proves that the developmental cancer drug, RRx-001, alkylates the hemoglobin beta chain

May 2013, Kingston, Ontario
Abstract: RRx-001, a hypoxia activated, nitric oxide generating cytotoxic agent: Phase 1 study results

April 2013, Washington, D.C.
Abstract: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent

January 2013, La Jolla, California
Abstract: Antivascular activity of RRx-001 in SCCVII and U87 tumors

Abstract: RRx-001: A novel hypoxia activated nitric oxide generating vascular disrupting agent (VDA)

Abstract: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent

December 2012, Atlanta Georgia
Abstract: Treatment with a novel dinitroazetidine, ABDNAZ, improves nitrite reductase activity of sickle red blood cells

March 2012, Chicago Illinois
Abstract: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors

December 2011, San Diego, California
Abstract: NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells

April 2011, Atlanta, Georgia
Abstract: Disposition of 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys, and humans

April 2011, Orlando, Florida
Abstract: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials’